Twist Bioscience Corporation announced on August 19, 2025, the launch of the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel. This customizable, research-use-only solution is designed to empower users to identify genomic alterations for a broad set of tumors.
The panel aims to guide targeted therapy development and support clinical and translational oncology research, offering a powerful alternative to locked, one-size-fits-all solutions. Its customizable content, flexible workflow, and compatibility with multiple sequencing platforms put scientific control back in the hands of researchers.
The panel incorporates a comprehensive and updated biomarker list covering 562 genes across all major tumor types. It can detect base substitutions, insertions and deletions, copy number variations, gene rearrangements, and measure tumor mutational burden and microsatellite instability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.